Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348675 | 0.94 | PDE4B (0.41) | PDE4BMAPK1PDE7A | |
| SCHEMBL3428370 | 0.89 | PDE4B (0.40) | PDE4BMAPK1KCNH2CHRM3 | |
| SCHEMBL4349750 | 0.89 | PDE4B (0.40) | PDE4BJAK1JAK3MAPK1KCNH2 | |
| SCHEMBL3428333 | 0.89 | PDE4B (0.45) | PDE4BMAPK1CHRM3 | |
| SCHEMBL4346115 | 0.89 | CHRM3 (0.40) | PDE4BMAPK1KCNH2CHRM3 | |
| SCHEMBL4352295 | 0.89 | PDE4B (0.44) | PDE4BMAPK1CHRM3 | |
| SCHEMBL4349939 | 0.87 | PDE4B (0.45) | PDE4BMAPK1CHRM3 | |
| SCHEMBL4346765 | 0.87 | PDE4B (0.45) | PDE4BMAPK1CHRM3 | |
| SCHEMBL4349803 | 0.86 | CHRM3 (0.49) | KCNH2CHRM3 | |
| SCHEMBL3428586 | 0.86 | PDE4B (0.44) | PDE4BMAPK1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2247184-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | PDE4B 2/4885JAK1 1452/4885JAK3 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.